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Abstract
Ovarian cancer has one of the highest mortality rates of all gynecological cancers [13].
Further knowledge of risk factors for the growth of ovarian tumors would be beneficial in both
the treatment and prevention of this type of cancer. Previous research has shown a positive
correlation between diabetes and prostate tumor growth [22], The first aim of this study was to
determine the effect of diabetes of ovarian tumor growth. The second aim was to develop a
model to predict ovarian tumor growth based on the microenvironment within a patient’s body.
The hypothesis was that there would be a positive correlation between diabetes and ovarian
tumor volume. Data from fifty patients was collected from charts at Grady Memorial Hospital in
Atlanta, Georgia. Oxygen saturation, tumor volume, blood glucose level, and cancer stage were
gathered for each patient. The results contradicted the hypothesis; there was a negative
correlation found between blood glucose level and tumor volume. More data is needed to
determine if increased blood glucose could be an effective treatment of ovarian cancer,
particularly since there other health risks associated with elevated blood glucose levels. The
proposed mathematical model also needs modification in order to effectively bridge the gap
between the clinical and research aspects of the cancer field.
IRB approval: The study protocols were approved by the institutional review boards (IRBs) at the
corresponding institutions. Consent was waived by the IRB since, in this particular study, a retrospective
medical record review was utilized as a method ofdata collection. CSU Protocol number 18-024.
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1 Introduction
In 2014, 21,161 women in the United States were diagnosed with ovarian cancer, and
14,195 died as a result of this type of cancer [13]. Once ovarian cancer is diagnosed, the stage of
the cancer is determined according to its progression. Table 1.1 shows the description of each
stage according to the FIGO system for staging ovarian cancer.
Several factors, generally speaking, play a role in the progression and development of
cancer. T cells, oxygen levels, and glucose consumption can all affect the growth rate of tumors.
T cells, which are a type of immune cell, have been found to suppress tumor immunity, thus
rendering the body more susceptible to malignant cell proliferation [18]. Oxygen levels also
affect cancer proliferation. Cancer cells proliferate at a higher rate than do blood vessel cells.
Because of this, the blood vessels, which carry oxygenated blood, cannot reach the inside of the
tumors that are formed due to the high rates of proliferation. This leads to a hypoxic
environment. Many cancer cells, including breast cancer cells, form solid tumors, resulting in a
hypoxic environment inside the tumor [14]. Although tumors arising from ovarian cancers are
epithelial in nature rather than solid, these tumor cells still experience hypoxia [16]. In the
presence of oxygen, cells receive 36 ATP after undergoing glycolysis, which fuels the cell
cycle,allowing cells to proliferate. Without oxygen, a hypoxic environment, cells undergo
fermentation, producing lactic acid and much lower amounts of ATP. Because the cells must rely
solely upon the ATP produced during lactic acid formation and fermentation, they only receive 2
ATP instead of 36. In order to counteract this hypoxic environment, the tumor must resort to
using glucose outside of the cell to obtain the energy needed to proliferate [19]. In this case, the
glucose source will be the blood stream. This is done by increasing the expression of glucose
transporters GLUT1 and GLUT3, which alter the structure of the tumor so that glucose outside
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of the cells can supply the cells with the necessary glucose to produce the ATP needed for
proliferation [15]. Since a higher blood glucose level would supply the cancer cells the glucose
needed for proliferation, it is thought that Type 2 diabetic patients, who have excess glucose in
their blood stream, could exhibit increased ovarian cancer cell proliferation. Table 1.2 shows the
stage of diabetes according to HbAlc, and Table 1.3 shows the stage of diabetes based on blood
glucose level while fasting.
The two aims of this study are:
1. To propose a mathematical model involving blood glucose levels, oxygen, and T cell
competition that can accurately predict ovarian tumor growth and proliferation.
2. To determine the effect of blood glucose levels on ovarian cancer tumors growth and
stage.
The first aim of this study attempts to develop a mathematical model that accounts for
oxygen levels and glucose levels in patients with type 2 diabetes in order to determine tumor cell
growth and T cell proliferation. We proposed two models for tumor growth within diabetic
patients based on previous modeling studies that have been conducted on the progression of
tumors [1-12].
Previous research has shown a positive correlation between diabetes and prostate cancer
growth [22]. Due to this, the hypothesis for this study for the second aim of the study was that
there would be a positive correlation between diabetes and ovarian cancer stage and a positive
correlation between diabetes and tumor size.
       
  
    
 
             
 
       
 
  
 
         
 
        
  
              
   
 
        
 
      
  
           
           
   
 
     
     
     
 
         
   
 
         
        
 
         
        
  
     
  
     
 
         
            
        
  
  
 
 
 
 
 
 
 
 
 
         
   
   
 
 
 
 
 
 
3
Table 1.1. FIGO ovarian cancer staging.
Stage I: Tumor confined to ovaries
IA Tumor limited to 1 ovary, capsule intact, no tumor on surface, negative washing
IB Tumor involves both ovaries otherwise like IA
IC1 Surgical spill
IC2 Capsule rupture before surgery or tumor on ovarian surface
IC3 Malignant cells in the ascites or peritoneal washings
Stage 2: Tumor involves 1 or both ovaries with pelvic extension (below the pelvic brim) or
primary peritoneal cancer
IIA Extension and/or implant on uterus and/or fallopian tubes
IIB Extension to other pelvic intraperitoneal tissues
Stage III: Tumor involves 1 or both ovaries with cytologically or histologically confirmed
spread to the peritoneum outside the pelvis and/or metastasis to the
retroperitoneal lymph nodes
IIIA1 Positive retroperitoneal lymph nodes only
IIIA1 (i): Metastasis < 10mm
IIIA1 (ii): Metastasis > 10mm
IIIA2 Microscopic, extrapelvic (above the brim) peritoneal involvement ± positive
retroperitoneal lymph nodes
IIIB Macroscopic, extrapelvic, peritoneal metastasis < 2cm ± positive retroperitoneal
lymph nodes. Includes extension to capsule of liver/spleen.
me Macroscopic, extrapelvic, peritoneal metastasis > 2cm ± positive retroperitoneal
lymph nodes. Includes extension to capsule of liver/spleen.
Stage IV: Distant metastasis excluding peritoneal metastasis
IVA Pleural effusion with positive cytology
IVB Hepatic and/or splenic parenchymal metastasis, metastasis to extra-abdominal organs
(including inguinal lymph nodes and lymph nodes outside of the abdominal cavity)
Table 1.2. Stage of diabetes based on HbAlc.
HbAlc (%) HbAlc (mm/L)
Nondiabetic <6.0 <42
Prediabetic 6.0-6.4 42-47
Diabetic >6.4 >47
Table 1.3. Stage of diabetes based on blood glucose
levels while fasting._
Blood Glucose (mg/dL)
Nondiabetic 0-100
Prediabetic 101-125
Diabetic 126+
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2 Glucose, Tumor and T cell model
In the following model, we are interested in the impact of glucose (G) on the growth of T
cells (7) and tumor cells (7):
.s th(C.)T h2(C)I
constant supply consumed by Tumor cells consumed by immune-cell
(2.1)
proliferation competition
~ = M<7)A2/~ j//
natural death competitionproliferation nat1iral
In the model, G(t) represents the concentration of glucose level in patients, which varies
with time t. The unit of G(t) is g/ml. Variable T(t) represents the total number of ovarian cancer
cells in patients. As previously mentioned, ovarian cancer cells are epithelial in nature and spread
on the surface of the ovary with a thinner layer of tumors cells oriented side-by-side rather than
on top of one another in a spherical nature as in most cancers. If T(t) is divided by the
concentration of ovarian cancer cells in per unit square area, we can convert T(t) into the total
surface area of ovarian cancer. The surface area of ovarian cancer is a commonly used clinical
criteria by physicians to determine the stage of cancer. In most clinical data sets, the area of
ovarian cancer is recorded. Therefore, we can easily fit the clinical data to T(t) by converting the
surface area to the approximate number of tumor cells by multiplying the concentration of the
tumor cells in a unit square area. Variable I(t) is the total number of immune cells in the affected
cancerous tissue.
                
                
             
              
     
 
 
   
 
              
               
                
                  
  
    
  
 
       
 
      
 
     
     
 
     
 
     
 
         
 
  
 
     
 
     
  
 
     
 
     
 
     
 
     
5
For immune cells, we consider the natural death rate d. However, for tumor cells, we
ignore the natural death rate because tumor cells have a very low rate of apoptosis [17].
Therefore, the natural death rate of cancer cells is negligible in the model.
The Michaelis-Menten kinetics is adapted for the per capita growth rate of tumor cells
(7=1) or immune cells (7=2):
biG
M<7) (2.2)1 \ kiG
By manipulating the constant supply of glucose s, we can mimic the different glucose
levels in patients with or without diabetics. Parameter A.i=l/20, where 20 hours is the doubling
time for tumor cells. Parameter A2=l/36, where 36 hours is the doubling time for immune cells
[20], The time t is measured in hours. Table 2.1 shows defines the variables for all equations in
this study.
Table 2.1. Variables defined.
Variable Description
I(t) Total amount of immune cells within tumor
T(t) Total number of ovarian cancer cells
G(t) Total glucose available within tumor
s Constant supply of glucose
d Death rate of immune cells
m Half-saturation constants for Michaelis-Menten kinetics
bi Maximal growth rate of immune cells or tumor cells
1/kt Half-saturation rate
Cl Competition ratio for tumor cells
C2 Competition ratio for immune cells
0 Oxygen
hi Proliferation ratio for tumor cells
h2 Proliferation ratio for immune cells
2/ Doubling time for tumor cells
2-2 Doubling time for immune cells
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3
4
A comprehensive model with Oxygen and Glucose
Since patients with type 2 diabetes have a higher glucose concentration in blood, the
extra glucose may be used to increase tumor growth and proliferation. However, even with a
sufficient supply of sugar, the growth of the tumor is still limited by the availability of oxygen.
With this in mind, the following comprehensive mathematical model is proposed (3.1). In the
following model, the impact of both glucose (G) and oxygen (O) on the growth of immune cells
(7) and tumor cells (T) are accounted for:
f d()
dT h((>)T hiO)l
constant supply consumed by 'lUmor cells consumed by immune-cell
lh{C)T th(C)l
constant supply consumed by Tljmor cells (3.1)
<li
natural death competitionproliferation
where functions min {fi{0), hi(G)}, and min {/2(G), /12(G)} are used since sources of oxygen and
glucose come from different places, but are essential for the proliferation of cancer cells. Each
substance fulfills different physiological needs with respect to growth [21].
Methods
De-identified patient data was collected by Dr. De’smond Henry, MD at Morehouse
School of Medicine. The data was obtained from the Georgia Cancer for Excellence at Grady
Memorial Hospital in Atlanta, Georgia. Fifty patients who had ovarian cancer were included in
the study. Diabetic patients whose diabetes was controlled with medication were excluded from
              
                 
                
                 
                
                
       
  
             
        
 
 
 
 
 
 
                
             
           
7
the study. Tumor volume, blood glucose level, oxygen saturation, HbAlc (for those with
diabetes), and stage of ovarian cancer were collect from the medical records of each of the fifty
patients. For patients who underwent surgery, the data was collected at the time of surgery. For
those who opted out of surgery, the data was collected at the time of diagnosis. Patients were
assigned a diabetic stage according to Table 3. The data was then analyzed to determine the
effect of diabetes on ovarian cancer. The data will be used for later incorporation into the
models that were developed for this study.
5 Results
Graph 5.1 shows the percentages for each stage of cancer within the study.
Graph 5.1. Percentage for each stage of cancer.
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The data was broken down into both stage and diabetic category in Graph 5.2. There was
no correlation between diabetic category and stage of cancer, although overall the greatest
percentage in each stage of cancer was comprised of nondiabetic patients.
             
     
      
                
                
         
        
   
      
 
 
           
  
Graph 5.2. Percentage for each diabetic stage across all stages of ovarian cancer.
Stage 1 Stage 2 Stage 3 Stage 4
■ nondiabetic ■ prediabetic ■ diabetic
Oxygen was found to have no correlation with cancer stage, as is shown in Graph 5.3.
Darker circles indicate a greater number of data points at this particular position on the graph.
All of the oxygen saturations were 94% or greater.
Graph 5.3. Oxygen saturation vs stage of cancer.
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9
Contrary to the hypothesis, there was no correlation between glucose and stage of cancer,
which is shown by Graph 5.4.
Graph 5.4. Blood glucose level vs stage of cancer.
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Glucose Level (mg/dL)
A negative correlation was found between diabetes and tumor volume, which contradicts
the hypothesis. This is shown in Graph 5.5. This data corresponds to Graph 5.6, which shows a
negative correlation between blood glucose level and tumor volume. This also contradicts the
hypothesis.
Graph 5.5. Average tumor volume for each diabetic stage.
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Graph 5.6. Blood glucose level vs tumor volume.
There was also a negative correlation between tumor volume and stage of cancer, as is
shown in Graph 5.7.
Graph 5.7. Stage of cancer vs tumor volume.
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6 Discussion
Both hypotheses were rejected. There was a negative correlation between diabetes and
tumor volume; and, between blood glucose levels and tumor volume. This is surprising, as the
opposite was found to be true for prostate cancer [22], It is possible that ovarian cancer could be
affected differently by glucose due to differences in the structure of most ovarian tumors, as they
are more epithelial in nature (less spherical) and therefore experience less hypoxia. This could
lead to a lesser need for angiogenesis and the development of a neovasculature system that
utilizes glucose and oxygen from the patient’s bloodstream. These surprising results could also
be attributed to the fact that different cancers behave differently and consequently react
differently to different microenvironments within the patient. It is worth further research to
determine whether or not it would be advantageous for ovarian cancer patients to have higher
levels of blood glucose in order to slow the rate of tumor growth.
It is also important to note that tumor stage was not correlated to blood glucose level and
that tumor volume had a negative correlation to cancer stage. This suggests that blood glucose
level only affects the size of the tumor and not necessarily stage of the cancer, as stage describes
the spread rather than the size of the tumors. Additionally, there might be a more accurate way of
measuring oxygen availability for the tumor other than oxygen saturation measurements for the
patient. Tumor volume could also be more accurately measured using volume displacement
methods. Overall, there are some limitations due to variations in data that is available from
patient charts.
These limitations make it difficult to utilize the models in this study, as there was no way
to measure T cell competition for any of the patients. Due to this, the models may have to be
modified in order to bridge the gap between the clinical and research aspects.
                  
                  
               
                 
               
               
                  
          
12
In the future, plans are underway to incorporate more patients into the data set. As can be
seen by the negative R2 values for the exponential regressions on Graph 6 and Graph 7, a greater
number of patients could potentially give more information to this study, as negative R2 values
can be indicative of a low number of data points. Additionally, plans are underway to repeat this
study with breast cancer patients. After sufficient data has been collected for both types of
cancers and modifications have been made to the models, research which include plans to utilize
the models to accurately predict the effect (if any) of glucose on the growth rate of tumors in
both ovarian cancer patients and breast cancer patients will ensue.
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